LP
NKTR icon

LMR Partners’s Nektar Therapeutics NKTR Stock Holding History

LMR Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98M Buy
100,000
+51,706
+107% +$3.78M 0.03% 543
2026
Q1 		$3.47M Buy
+48,294
New +$2.75M 0.01% 736
2022
Q2 		– Sell
-4,085
Closed -$330K – 1405
2022
Q1 		$330K Sell
4,085
-330
-7% -$48.8K ﹤0.01% 1058
2021
Q4 		$895K Buy
+4,415
New +$958K 0.01% 771
2020
Q1 		– Sell
-11,731
Closed -$3.8M – 384
2019
Q4 		$3.8M Buy
+11,731
New +$3.4M 0.01% 92
2018
Q4 		– Sell
-832
Closed -$761K – 437
2018
Q3 		$761K Sell
832
-7,875
-90% -$6.72M 0.05% 154
2018
Q2 		$6.38M Buy
+8,707
New +$10M 0.33% 74

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's NKTR Position: Q2 2026 in Review

LMR Partners increased its Nektar Therapeutics (NKTR) stake by 107% in Q2 2026, buying an estimated $3.78M and bringing the position to 100,000 shares worth $6.98M. The position accounts for 0.03% of the portfolio, ranked #543.

LMR Partners first reported a position in NKTR in Q2 2018 and has held it in 7 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • LMR Partners held 100,000 shares of Nektar Therapeutics worth $6.98M as of Q2 2026.
  • LMR Partners bought 51,706 Nektar Therapeutics shares in Q2 2026, an estimated $3.78M.
  • Nektar Therapeutics made up 0.03% of LMR Partners's portfolio in Q2 2026, its #543 holding.
  • LMR Partners first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 7 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.